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Plasma and urinary catecholamines as related to renal function in man.
To assess the relationship between renal plasma flow (ERPF) or
glomerular filtration rate (GFR) and the levels of norepinephrine (NE)
or epinephrine (E) in plasma or urine in the presence of progressive
degrees of non-oliguric renal functional impairment, these variables
were assessed simultaneously in 18 normal subjects, 72 with parenchy-
mal kidney disease and 14 with essential hypertension. ERPF and GFR
were lower (P < 0.01 to 0.001) in the groups with renal disease (mean
SD, 340 230 and 68 43 mI/mm/I .73 m2, respectively) or essential
hypertension (434 101 and 97 25 ml/min/l.73 m2) than normal
subjects (597 133 and 118 14 ml/min/l.73 m2). Plasma and urinary
NE and E did not differ significantly among groups and were unrelated
with ERPF or GFR (range 4 to 160 ml/min/l.73 m2), except for reduced
(P < 0.001) urinary NE and E excretion in the presence of a GFR < 20
mI/mm. Subgroups with renal disease and a normal (N = 39) or high
blood pressure (N = 33) also were comparable in their plasma and
urinary NE and E, while ERPF and GFR tended to be lower in
hypertensive patients. It is concluded that a chronic reduction in
excretory kidney function may have no relevant impact on circulating
levels of NE and E per se, although their urinary excretion falls
distinctly at the stage of advanced renal failure. These aspects deserve
consideration when pathogenetic or diagnostic studies of catechola-
mines are performed in normotensive or hypertensive patients with
impaired kidney function.
[31. The bladder was catheterized and an intravenous cannula
was inserted at least 40 minutes before initial blood sampling on
the arm contralateral to the one used for infusion. Following
equilibration, two consecutive 20-minute urine collections and
midline venous blood samples for determination of 51Cr-EDTA,
PAH, creatinine (by Greiner autoanalyzer, Greiner SA, Lan-
genthal, Switzerland) and potassium (by flame photometer)
were obtained; NE and E were always measured [4, 5] during
the second clearance period, and in 28 subjects also during the
first period. Mean co-efficient of interassay variation for 110
unselected consecutive determinations was 9.8 6.5% (± SD)
for plasma NE; 12.5 9.4% for plasma E; the co-efficient of
interassay variation for control plasma was 2% for plasma NE;
and 2.5% for plasma E. Statistical methods included analysis of
variance and modified f-test (two tailed) to compare study
groups, and the Wilcoxon rank order for intra-individual com-
parisons. The natural logarithmic transformation of NE and E
[5] was used.
Results
Variation between consecutive clearance periods
Considering a paucity of data on the relationship between
renal plasma flow (ERPF) or glomerular filtration rate (GFR)
and the levels of catecholamines in both blood and urine [1, 21,
these variables were assessed in 18 normal subjects (NP), 14
patients with essential hypertension (EHT) and 72 with renal
parenchymal disease (RPD). In the latter group, 32 patients had
chronic glomerulonephritis, 11 interstitial nephritis, four dia-
betic nephropathy, three polycystic kidney disease, four
chronic rejection of a renal transplantant, and 18 miscellaneous
lesions. No patient had hypertensive—retinopathy Keith Wage-
ner stage III or IV, edema or heart failure. When given
previously, antihypertensive drugs were discontinued for at
least two weeks before study, All subjects gave their informed
consent to the study.
Methods
GFR and ERPF were determined between 8 and 12 a.m. in
the supine position using 51Cr-EDTA and PAH, respectively
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In the 28 subjects in whom catecholamines were measured
during two consecutive clearance periods, no significant varia-
tions between these periods were noted. GFR averaged 74 50
and 73 50 ml/min/1.73 m2, respectively, ERPF 335 203 and
352 220 ml/min/1.73 m2, plasma NE 38.5 16 and 38.1 18
ng/dl, plasma E 6.5 6.3 and 5.3 6.2 ng/dl, urinary NE
excretion rate 19.2 30 and 16.7 19 ng/min, and E excretion
rate 9.1 13 and 12.3 24 ng/min. Mean values of these results
were used for further analysis.
Mean values in study groups and subgroups
GFR and ERPF were lower in patients with EHT and
particularly those with RPD than in NP (P < 0.01 to <0.0001).
Urine flow and electrolyte excretion rates were decreased in
RPD (P < 0.01 to <0.0001). Mean age, plasma NE and E, and
urinary catecholamines expressed relative to creatinine excre-
tion rates tended to be higher in RPD or EHT than in NP (Table
1). However, absolute urinary NE and E excretion rates were
lower (P < 0.01 and < 0.05, respectively) in RPD than in NP.
As expected [5], plasma NE correlated positively with age in
NP (r = 0.69, P < 0.01) but not in the other groups. No
significant correlations between plasma E or absolute urinary
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Table 1. Blood pressure, plasma and urinary catecholamines, electrolytes, and renal function in the study groups (mean SD)
Renal disease Essential
hypertension
>150/100Normotensive Hypertensive
Normal subjects <140/90 mm Hg >150/95 mm Hg All mm Hg
N 18 39 33 72 14
Female/male 6/12 35/37 6/8
Age (years) 24.8 4.6 39.0 15.6" 43.6 13.6" 41.1 14.7" 49.2 14.5"
Blood pressure, mm Hg
Systolic 131 14 132 12 162 23 146 23 183 20
Diastolic 85 8 82 8 105 11 93 15 119 14
Plasma creatinine, mol/1iter 87 11 155 ll3' 238 226" 193 177" 90 19
Glomerular filtration rate
mI/min/1.73 m2 118 14 81 44" 53 37" 68 43' 97 25"
Effective renal plasma flow,
ml/min/1.73 m2 597 133 426 245C 237 161" 340 230' 434 l0l1
Plasma sodium, mmol/liter 141 3 140 3 140 4 140 4 140 3
Potassium, mmol/liter 3.8 0.3 3.8 0.6 4.2 0.6 4.0 0.7 3.8 0.7
Norepinephrine, ng/dl 27 12 31 16 36 l6' 33 16 37 27
Epinephrine, ng/dl 4.6 2.0 6.9 6.9 8.8 6.8" 7.7 6.9" 6.0 2.8
Urinary excretion rate,
Volume, mI/mm 4.1 2.6 1.6 11b 1.7 07b 1.7 1.0" 4.2 2.7
Sodium, pinol/min 301 274 78 90" 75 67" 77 80" 293 262
Potassium, jsmol/min 119 78 30 41b 30 30b 28 36 70 60
Norepinephrine, ng/min 30 20 10 411 14 18" 12 13" 30 23
ng/mg creatinine 29 14 38 25 69 114 51 78 47 23"
Epinephrine, ng/min 13 10 5 5" 7 13 6 10" 11 9
nglmgcreatinine 11 5 19 14 25 51 21 35" 18 Ii"
Total catecholamines, ag/mm 43 28 15 1!" 21 301 18 22" 41 29
a P < 0.0001
b P < 0.001
P < 0.01
d P < 0.05 vs. normal subjects
NE or E excretions and age were noted. Plasma E tended to be
slightly higher in RPD than in NP.
A comparison between RPD subgroups with a normal or high
BP revealed a tendency for a lower GFR and ERPF in the latter
(Table 1). Plasma and urinary catecholamine and electrolyte
values did not differ significantly between these subgroups.
Relationship between urinary and plasma catecholamines
Plasma NE or E levels did not correlate with absolute urinary
NE or E excretion rates in NP, EHT or RPD with normal or
high BP.
Catecholamine values as related to renal function
Considering subgroups of subjects stratified according to
their GFR, no significant variation in plasma NE and E with
decreasing renal function was apparent (Table 2). Individual
catecholamine excretion rates in RPD tended to be very vari-
able. Thus, mean NE or E excretions, expressed either as
absolute rates or relative to creatinine excretion, did not differ
significantly between subjects with a GFR  95 ml/min/l.73 m2
and those with a GFR in the range of 20 to 49 ml/min/l.73 m2.
However, urinary NE excretion expressed as absolute rate or
relative to creatinine excretion, as well as the absolute E
excretion rate were lowered significantly (P < 0.0001) in all
subjects with a GFR < 20 ml/min/l.73 m2; a similar tendency
occurred also in the normotensive and hypertensive subgroups
with RPD. Moreover, a regression analysis corroborated the
absence of a significant correlation between plasma NE or E
and GFR or ERPF in all groups studied and the tendency for
decreasing urinary catecholamine excretion rates in advanced
renal failure (Fig. 1).
Urinary electrolytes as related to other study parameters
Except for a positive correlation between urinary potassium
excretion rate and GFR or ERPF (r = 0.56 or 0.53, respectively,
P < 0.05), no significant relationship between sodium or potas-
sium excretion and GFR, ERPF, plasma creatinine, plasma NE
or E, BP or age, existed in any group, subgroup or all subjects
analyzed jointly.
Relationship with BP
In the group with RPD, mean BP correlated significantly with
age in the normotensive (r = 0.32, P < 0.05), but not in the
hypertensive (r = 0.04) or all patients (r = 0.12). Mean BP
correlated in the entire group also inversely with ERPF (r =
—0.31, P < 0.01) or GFR (r = —0.23, P < 0.01). No other
significant correlations between BP and additional study param-
eters were apparent in the different groups.
Discussion
The present findings demonstrate that a chronic reduction in
excretory kidney function may per se have no relevant impact
on circulating levels of NE or E, although the urinary excretion
of the catecholamines falls distinctly at the stage of advanced
renal failure (GFR < 20 ml/min/l.73 m2). This reduction seems
to be partly, but not exclusively, the result of reduced urine
Normal subjects N
Plasma NE, ng/dl
E, ngldl
Urinary NE, nglmin
nglmg creatinine
E, ng/min
ng/mg creatinine
Na, mol/min
K mol/min
Normotensive renal disease N
Plasma NE, ng/dl
E, ng/dl
Urinary NE, ng/min
ng/mg creatinine
E, ng/min
nglmg creatinine
Nat, molIminK , imolImin
Hypertensive renal disease N
Plasma NE, ng/dl
E, ng/dl
Urinary NE, ng/min
ngl,ng creatinine
E, ng/min
nglmg creatinine
Nat, j.unollmin
K , j.mo1Imin
Essential hypertension N
Plasma NE, ngldl
B, ngldl
Urinary NE, ng/min
ng/mg creatinine
B, ng/min
ng/ing creatinine
Na, molImin
K , ,amol/min
All subjects N
Plasma NE, ng/dl
E, ngldl
Urinary NE, ng/min
ng/mg creatinine
E, nglmin
nglmg creatinine
Nat, mol/min
K, j.unol/min
a p < 0.05
b p < 0.01
P < 0.001
d P < 0.0001
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27 12
4.6 1.4
30.4 19.9
29 14
13.0 9.8
11 5
301 274
199 78
17
32 13
7.9 9.1
10.7 5.6
39 14
5.1 4.8
17 13
77 45
19 13
4
43 15
10.3 5.5
16.3 9.4
40 11
7.4 5.2
17 7
76 22
14 5
9
29 10
6.1 2.7
32.8 24.9
47 22
11.4 7.7
18 12
308 241
67 51
48
31 13
6.5 6.0
22.7 19.0
36 17
9.5 8.2
16 12
210 228
67 70
10
27 16
6.9 5.4
13.1 11.6
54 42
5.4 4.9
20 15
60 49
22 18
14
41 18
7.2 5.2
11.0 6.2
88 156
4.3 2.9
18 12
87 89
37 42
5
50 42
5.8 3.2
18.8 6.3
46 25
9.6 10.4
32 23
258 342
78 84
29
38 24
6.8 4.9
13.1 87b
65 100
5.6 5•5a
18 12
105 154
38 46
7
24 7
6.8 4.8
9.3 5.2
29 14
6.4 6.6
21 17
54 38
26 11
8
33 15
12.3 10.7
25.3 32.5
117 134
13.0 26.7
58 108
61 27
26 13
15
29 13
9.7 8.7
17.8 24.7
67 93
10.0 19.7
36 69
57 32"
26 12
5
44 29
4.1 2.6
2.2 04"
18 13
3.4 2.9
17 12
148 222
81 96
7
25 6
7.1 3.6
5.3 3.6
13 6
2.9 1.8
10 8
64 76
30 25
12
32 20
5.9 3.5
4.0 3•1d
15 9"
3.1 2.2"
13 10
103 156
53 68
flow rates. The lack of more distinct alterations in circulating
catecholamines with progressive degrees of non-oliguric
chronic renal impairment (range of GFR, 160— 4 mllmin/1 .73
m2) is consistent with the observation that the kidneys contrib-
ute at least under normal conditions <10% [6, 7] to the plasma
clearance of NE [8—10] and <15% [6, 7] to that of E [10].
However, at the stage of terminal renal failure plasma catechol-
amines tend to rise [11, 12]. The hypercatecholaminemia occur-
ring in uremia may be due to a reduced neuronal re-uptake and
metabolism [11, 13].
Others reported elevated plasma NE levels in six hyperten-
sive patients with a creatinine clearance < 35 mI/mm and hyper-
tension, but neither a normotensive control group with similar
renal function nor simultaneous measurements of circulating E
were available [1]. Our 39 normotensive and 33 hypertensive
patients with RPD did not differ significantly in their plasma and
urinary NE or E, while ERPF and GFR tended to be lower in
the hypertensive subgroup. It follows that hypertension accom-
panying non-oliguric renal functional impairment can often not
be explained by altered peripheral catecholamine levels. The
somewhat high basal plasma NE values [5] in our healthy
volunteers suggest that the subjects may have been aroused due
to the experimental procedure. Moreover, the slightly higher
mean plasma NE concentration in the hypertensive patients
Table 2. Plasma catecholamines and urinary catecholamine and electrolyte excretion rates in subgroups
with different renal function (mean su)
Glomerular filtration
Groups and parameters 95 50—94
rate (ml/min/l .73 m2)
20—49 4—19
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with RPD or EHT as compared with NP may well be explained
by a difference in age [5]. Nevertheless, differences related to
the etiology of the kidney disease may exist, since plasma NE
and E levels in chronic glomerulonephritis were reported to
correlate positively with BP [14].
Blood levels of catecholamines per se are a poor indicator of
their role in BP regulation. An exaggerated cardiovascular
reactivity relative to existing NE activity may play a pathogenic
role in EHT [15—171 as well as hypertension accompanying
early renal functional impairment [21; while hypertension in
hemodialysis patients strongly depends on another NE-related
mechanism [18]. The findings of the present study have also
diagnostic implications. Based on observations in 14 patients
only, it was postulated that plasma levels of total catechola-
mines are elevated in the presence of mild—to—moderate renal
functional impairment, thus, rendering plasma catecholamine
measurement useless in a diagnostic search for pheochromocy-
toma [191; however, the different catecholamines, namely, NE,
E and dopamine were not determined separately. The largely
unaltered plasma NE and E concentrations in our larger study
population suggest that such measurements may retain diagnos-
tic usefulness, while urinary NE and E excretions, expressed as
absolute rates or relative to creatinine excretion, tend to
become unreliable when a pheochromocytoma is suspected in
the presence of advanced, yet non-oliguric renal failure.
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Fig. 1. Absolute urinary catecholamine
excretion rates as related to renal function in
normal subjects and patients with renal
disease or essential hypertension. Symbols
are: (0) normal subjects; (•)essential
hypertension; () renal disease,
normotensive; (A) renal disease,
hypertensive.
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